Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1972/10 (Botulinum toxin/ALLERGAN) 10-03-2015
Facebook X Linkedin Email

T 1972/10 (Botulinum toxin/ALLERGAN) 10-03-2015

European Case Law Identifier
ECLI:EP:BA:2015:T197210.20150310
Date of decision
10 March 2015
Case number
T 1972/10
Petition for review of
-
Application number
03015590.7
IPC class
A61K 38/48
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 355.59 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Use of the neurotoxic component of Botulinum toxin for treating muscle spasm

Applicant name

Allergan Inc.

Merz Pharma GmbH & Co. KGaA

Opponent name
Solstice Neurosciences, Inc. (opposition withdrawn)
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 76(1)
Keywords
Divisional application - added subject-matter (yes)
Catchword
-
Cited decisions
G 0001/06
Citing decisions
T 1036/11

I. An appeal was filed by the patent proprietors (appellants) against the decision of the opposition division to revoke European patent No. 1 366 771. The patent is entitled "Use of the neurotoxic component of Botulinum toxin for treating muscle spasm".

II. The revoked patent was filed as European patent application No. 03 015 590 which was a divisional application of parent European application

No. 99 203 920, published as EP 1 005 867, which itself was a divisional of European application No. 95 906 674, published as international application No. WO 95/17904. In due course an opposition was filed by Solstice Eurosciences, Inc.

III. In the written reasons for decision under appeal dated 19 July 2010, the subject-matter of claim 1 of the patent was found not to satisfy the requirements of Article 76(1) EPC because it was not clearly and unambiguously derivable from the disclosure of the parent and grandparent applications with respect to the feature of claim 1 "the neurotoxic component of a Botulinum toxin". In particular, both the parent and grandparent application did not directly and unambiguously disclose the claimed use of the neurotoxic component of a Botulinum toxin isolated from neurotoxin associated proteins (NAPs) (emphasis added by the board).

IV. With a letter dated 17 November 2010, the opposition was withdrawn.

V. Following a communication of the board setting out its preliminary appreciation of the substantive and legal matters concerning the appeal, the appellant submitted a new main request and five auxiliary requests with a letter dated 10 February 2015.

VI. Claim 1 of this main request is identical to claim 1 as granted and reads:

"1. Use of the neurotoxic component of a Botulinum toxin for the manufacture of a medicament for the treatment of a spastic muscle by means of intramuscular injection, whereby medicaments for the administration to a patient of a Botulinum toxin of a selected serotype until the patient develops neutralizing antibodies, and thereafter administration to the patient of another Botulinum toxin of a different serotype, are excluded".

VII. Oral proceedings before the board took place on 10 March 2015.

VIII. The requests of the appellants at the oral proceedings were that the decision under appeal be set aside and the patent be maintained on the basis of the main request, alternatively on the basis of one of the first to fifth auxiliary requests, all as filed with their letter dated 10 February 2015, alternatively that the case be remitted to the opposition division for further prosecution on the basis of one of these requests. At the end of the oral proceedings the chairwoman announced the decision of the board.

IX. The following documents are mentioned in this decision:

D1: WO 95/17904, published 6 July 1995, filed on 16 December 1994 and claiming a priority dated 29 December 1993 (the grandparent application).

D2: EP-A-1 005 867, published 7 June 2000 (the parent application).

D5: Moyer, Elizabeth, and P. E. Setler. "Botulinum toxin type B: Experimental and Clinical Experience"; In: "Therapy with Botulinum Toxin", edited by Jankovic J. and Hallet M., February 1994, 71-78.

D16: Declaration of Dr. Mitchell Brin dated 10 September 2010.

D17: Declaration of Dr. Leonard Smith dated 10 September 2010.

X. The arguments of the appellants can be summarised as follows:

All requests

Article 76(1) EPC

The term "Botulinum toxin" would have been understood by the skilled person at the priority date to refer to the isolated neurotoxic component of Botulinum toxin, as well as to the neurotoxic component in complex with the neurotoxin associated proteins (NAPs). This was inter alia reflected in the description of the grandparent application, document D1, page 3, first two full paragraphs. Here it was disclosed that the neurotoxic component of Botulinum toxin had a molecular weight of 150 kD and consisted of a long 100 kD chain and short 50 kD chain, these chains being linked via a disulphide bridge. It was further known that certain serotypes of Botulinum toxin, e.g. type E, may exist in the form of a single chain un-nicked protein, as opposed to a dichain, the single chain form being less active but which may be converted to the corresponding dichain by nicking with a protease, e. g., trypsin.

It was explicitly stated in document D1 that both the single and the dichain were useful in the method of the present invention. This last sentence made no mention of the presence of any NAPs and would have led the skilled person, who was already aware that the term Botulinum toxin could mean the neurotoxic component alone, to conclude that both the single and dichain forms of the neurotoxic component in isolation from NAPs were useful in the method of the present invention, i.e. in the claimed use for the treatment of spastic muscle.

Furthermore, document D5, published in 1994, reflected how the skilled person at the priority date would have interpreted the expression Botulinum toxin. The first paragraph on page 72, headed "Structure of the Botulinum Toxin Type B. Toxin-Nontoxin Protein Complex" illustrated that the term Botulinum toxin was used to mean both neurotoxic component complexed with NAPs (i.e. L and M complexes) and the neurotoxic component on its own, i.e. the S or small form. It was telling that the S form was also referred to as the pure toxin protein. The expert declarations of documents D16 and D17 confirmed this interpretation.

It followed that the subject-matter of claim 1 of all requests was fully disclosed in document D1 and therefore met the requirements of Article 76(1) EPC.

1. The appeal is admissible.

Main Request

Article 76(1) EPC - added subject-matter

2. Article 76(1) EPC states that "a European divisional application [...] may be filed only in respect of subject-matter which does not extend beyond the content of the earlier application as filed". According to established case law of the boards of appeal, it is a requirement that the subject-matter of a divisional application must be directly and unambiguously derivable from the earlier application as filed. In the case of a sequence of divisionals consisting of a root (originating) application followed by divisional applications, each divided from its predecessor, anything disclosed in a divisional application must be directly and unambiguously derivable from what is disclosed in each of the preceding applications as filed (G 1/06, OJ EPO 2008, 307, headnote).

3. The subject-matter of claim 1, which is drafted in the Swiss-type format, is the medical use of the neurotoxic component of Botulinum toxin, where the use is the treatment of a spastic muscle by intramuscular injection.

4. As it is uncontested that claim 1 includes, at least as an embodiment, the use of the neurotoxic component of Botulinum toxin isolated from neurotoxin associated proteins, the question to be answered by the board with respect to the requirements of Article 76(1) EPC is therefore whether the skilled person at the priority date would have regarded this subject-matter as directly and unambiguously derivable from the disclosure of the grandparent application, document D1.

5. To answer the above question it is first to be established how the skilled person, at the priority date, would have interpreted the expression "Botulinum toxin", taking into account the common general knowledge at that date. In particular is to be decided whether the common understanding of a skilled person at the time was that a reference to "Botulinum toxin" inherently included a reference to the neurotoxic component on its own, stripped of other associated proteins.

6. The description of the grandparent application (document D1), being essentially identical to that of the patent in suit, gives a good picture of the relevant knowledge of the skilled person at the priority date, in particular in the section "Background of the Invention" (page 1, line 17, to page 3, line 19). Furthermore, the content of document D5, published in February 1994, very shortly after the priority date, namely 28 December 1993, may also be considered as reflecting the state of the art at and before that date.

7. In document D5 (page 72, 1st paragraph) it is disclosed that "Botulinum toxin" consists of a complex of proteins including nontoxin proteins and a neurotoxin. The latter was commonly referred to as the "neurotoxic component of Botulinum toxin" (see document D1 page 3, lines 5-14). Indeed, the term "component" already implies that the neurotoxin is just one constituent of a larger whole. Document D1 in its presentation of the background art defines the term "Botulinum toxin" as being "a generic term embracing the family of toxins produced by the anaerobic bacterium Clostridium botulinum [of which] seven immunologically distinct neurotoxins have been identified". "Botulinum toxin" is also used to refer to the products sold commercially for clinical use under the trade names "DYSPORT" and "BOTOX" (see document D1, page 4, lines 14 to 19), these being Botulinum toxin type A and being formulated in the form of the neurotoxic component in complex with nontoxin proteins which were also known as neurotoxin associated proteins (NAPs) (see document D5, page 72, paragraph 1).

8. Document D5 was referred to by the appellant as demonstrating that the expression "Botulinum toxin" was used in the art to mean both the complexed and pure form of the neurotoxin.

9. As is evident from the title, the document is a review of the experimental and clinical experience with Botulinum toxin type B. In the document the expressions "Botulinum toxin", the abbreviation "BTX" and the term "toxin" are all variously used. Careful reading shows that the first two are used when discussing Botulinum toxin as used clinically, i.e. in complex with NAPs (see for instance, page 71, line 1 and page 81, "Clinical uses of Botulinum toxin type B"). The term "toxin" is used to mean the neurotoxin present in this complex, as can be seen from the following passage from page 72, paragraph 1, cited as an example: "Formation of an association complex with nontoxin proteins appears to stabilize the activity of the BTXs perhaps by helping maintain a necessary secondary or tertiary structure. It is presumably for this reason that the only commercially available BTX for clinical use, type A, is formulated in the form of a toxin-hemagglutinin nontoxin protein complex, rather than as a formulation of pure toxin". (Emphasis added by the board).

10. It can be seen from the cited passage that the neurotoxic component is referred to as "toxin", while this component in isolated form is called "pure toxin". There is nothing in the disclosure of document D5 as a whole to suggest that the skilled person at the priority date would have generally considered that references to "Botulinum toxin" would have been understood by the skilled person as also referring to "pure toxin". Rather, the document read as a whole gives the opposite impression. It is disclosed that there was a general belief that it was beneficial to administer the toxin-hemagglutinin nontoxin protein complex for reasons of stability. Furthermore, given the careful differentiation made between the complexed and isolated neurotoxic component of Botulinum toxin ("pure toxin") and given that the only commercially available form of Botulinum toxin was in complex with NAPs, the skilled person would at the priority date have expected that in a situation where the neurotoxic component of Botulinum toxin was to be used stripped of the NAPs, this would have been explicitly mentioned.

11. The board concludes that the appellant's argument that the skilled person at priority date would have considered references to "Botulinum toxin" to include a reference to the neurotoxic component of Botulinum toxin on its own is therefore not convincing.

12. The board therefore concludes that the skilled person at the priority date would have understood the expression "Botulinum toxin" to mean the neurotoxic component of Botulinum toxin in complex with NAPs, as present, for example, in the commercially available preparations.

13. It remains to be considered whether the skilled person reading the grandparent application, document D1, in the light of this interpretation of the expression "Botulinum toxin", would have been able to directly and unambiguously derive the claimed subject-matter from this earlier application.

14. The only passages of document D1 pertaining to the neurotoxic component of the Botulinum toxin are found on page 3, lines 5 to 24, and are reproduced below:

"The neurotoxic component of Botulinum toxin has a molecular weight of about 150 kilodaltons and is thought to comprise a short polypeptide chain of about 50 kD which is considered to be responsible for the toxic properties of the toxin, i.e., by interfering with the exocytosis of acetylcholine, by decreasing the frequency of acetylcholine release, and a larger polypeptide chain of about 100 kD which is believed to be necessary to enable the toxin to bind to the presynaptic membrane.

The "short" and "long" chains are linked together by means of a simple disulfide bridge. (It is noted that certain serotypes of Botulinum toxin, e. g., type E, may exist in the form of a single chain un-nicked protein, as opposed to a dichain. The single chain form is less active but may be converted to the corresponding dichain by nicking with a protease, e. g., trypsin. Both the single and the dichain are useful in the method of the present invention.)" (emphasis added by the board).

15. These passages would have been read in the context of the application as a whole. In the paragraphs preceding the above citation it is explained that "Botulinum toxins, in particular Botulinum toxin type A, has been used in the treatment of a number of neuromuscular disorders" (page 1, line 20 to page 2, line 22). It is then explained that "the term Botulinum toxin is a generic term embracing the family of toxins produced by the anaerobic bacterium Clostridium Botulinum and, to date, seven immunologically distinct neurotoxins have been identified [which] have been given the designations A, B, C, D, E, F and G."

16. In the opinion of the board, the skilled person reading the passage of the description referring to the neurotoxic component would have read it in the context of the immediately preceding passages cited above, and would have seen it it as providing information about the structure and function of Botulinum toxin. Thus, the statement that "Both the single and the dichain are useful in the method of the present invention" would have been taken at face value, that is to say, that "Botulinum toxins" comprising the neurotoxic component either in nicked di-chain or unnicked single chain form could be used in the claimed medical use, but not as a disclosure that the neurotoxic component stripped of NAPs should be used in the disclosed invention.

17. The board cannot identify any other passage of document D1 that would have led the skilled person to the conclusion that the neurotoxic component stripped of NAPs should be used in the disclosed invention. Indeed the expression "Botulinum toxin" is used throughout document D1 and nowhere is there an explicit or implicit disclosure of the claimed use where that use is of the neurotoxic component stripped of NAPs. For example, the section of document D1 concerning the administration of the toxin (page 8, final paragraph to page 9, first paragraph), mentions the commercially available "Botulinum toxins", which consist of the neurotoxin in complex with associated proteins (see section 7.7. ). It follows that in this section the term can only mean the complexed form of the toxin.

18. Indeed, document D1 uses the terms "Botulinum toxin" and "neurotoxic component" carefully. The former is used in the examples while the latter is only mentioned once in the entire document (see the passage at page 3, under the heading "Background of the Invention"). This passage is a description of the structure and function of "Botulinum toxin".

19. The declarations of documents D16 and D17, made long after the priority date, were provided by the appellant as expert opinions on the disclosure of document D1. In document D16, the author, Dr. Brin, states his opinion that the skilled person reading document D1 would from the passage at page 2, which reads "Both the single and the dichain are useful in the method of the present invention", directly and immediately understand that it discloses the use of the isolated neurotoxic component of Botulinum toxin in the medical use claimed (see document D16, at page 3, item 16 (3)). Similarly, in document D17 at item 13, Dr. Smith uses identical language to reach the same opinion as Dr. Brin.

20. However, the board has in point 16 above already explained why it does not share this view. Moreover, the opinions expressed in documents D16 and D17 cannot override the available contemporary evidence nor can they be used to re-interpret the description of document D1 in a manner other than that which the skilled person at the priority date would have done.

21. In summary, the board concludes that the skilled person reading the passage in document D1 which states that "Both the single and the dichain are useful in the method of the present invention" would conclude that "Botulinum toxin" from all the various serotypes, including those that produce an un-nicked single chain variant, may be used in the invention but not that the single and di-chain variants of the neurotoxic component of Botulinum toxin in isolated from NAPs may be used in the invention.

22. The board therefore concludes that the grandparent application, document D1, does not directly and unambiguously disclose the claimed use of the neurotoxic component of Botulinum toxin isolated from neurotoxin associated proteins.

23. The subject-matter of claim 1 therefore does not meet the requirements of Article 76(1) EPC.

Auxiliary Requests 1 to 5

24. The medical use of the isolated neurotoxic component of Botulinum toxin is an embodiment of the subject-matter of claim 1 of each of these requests. The reasoning concerning the requirements of Article 76(1) EPC concerning claim 1 of the main request set out in points 2 to 23 above therefore applies equally to the subject-matter claim 1 of all auxiliary requests, which therefore do not meet the requirements of

Article 76(1) EPC.

Order

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility